基于AI的OCT系统检测糖尿病黄斑水肿:前瞻性验证与非劣效随机临床试验
该研究分两步评估AI-OCT系统在糖尿病视网膜病变筛查路径中检测糖尿病黄斑水肿(DME)的表现:前瞻性静默验证纳入603例糖尿病患者,系统检测DME敏感度98.8%、特异度90.7%;随后多中心非劣效RCT纳入276例疑似DME患者,干预组假阳性转诊率24.1%显著低于对照组69.1%,差异-45%,非劣效成立,且转诊敏感度均为100%。
要点
- AI-OCT系统检测DME敏感度98.8%、特异度90.7%。
- AI-OCT辅助筛查使假阳性DME转诊率从69.1%降至24.1%。
- 两组DME转诊敏感度均为100%,干预组未转诊者无DME发生。
核心结论
- 在标准筛查基础上加入AI-OCT作为二级筛查工具,假阳性转诊率非劣效于标准实践,并大幅减少不必要的DME转诊且不损害敏感度。
研究设计与样本
- 前瞻性静默模式验证于2020年2月至2023年7月在香港三级医院分诊单位招募603例糖尿病患者。
- 随后开展多中心非劣效RCT(2023年9月至2025年4月),招募276例疑似DME患者随机分为干预组137例和对照组139例。
主要发现
- 静默验证中1200次扫描有86次(7.2%)无法分级,1114次可分级扫描中49次(4.4%)被判定为不确定。
- 系统检测DME的敏感度为98.8%(95%CI 94.5%-100.0%),特异度为90.7%(95%CI 88.7%-92.4%)。
- RCT中干预组与对照组DME患病率相似(30.9% vs 29.9%)。
- 假阳性DME转诊率干预组为24.1%(95%CI 14.6%-37.0%),对照组为69.1%(95%CI 61.0%-76.1%),绝对差异-45%(95%CI -58.2%至-31.9%;非劣效P<.001)。
- DME转诊敏感度两组均为100.0%(95%CI 100.0%-100.0%),特异度干预组86.5%(95%CI 79.3%-92.9%),对照组0.0%(95%CI 0.0%-0.0%)。
关键数值与推荐
- 主要结局假阳性DME转诊率的预设非劣效界值为20%,干预组差异置信区间上限低于该界值。
- 干预组未转诊参与者中无DME病例发生。
临床怎么用
- 可将AI-OCT系统作为糖尿病视网膜病变筛查路径中的二级筛查工具,以减少不必要的DME专科转诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Screening for diabetic retinopathy using fundus photographs is the global standard of care but results in high false-positive referrals to evaluate diabetic macular edema (DME), placing a substantial burden on specialist eye clinics. Integrating an AI-based optical coherence tomography (AI-OCT) system into screening pathways may reduce potentially unnecessary referrals. OBJECTIVE: To evaluate the diagnostic and referral performance of an AI-OCT system for DME detection within a diabetic retinopathy screening pathway in clinical settings. DESIGN, SETTING, AND PARTICIPANTS: Stepwise evaluation conducted in Hong Kong Special Administrative Region: a prospective silent-mode validation (February 2020 to July 2023) recruiting 603 patients with diabetes at a tertiary hospital triage unit, followed by a multicenter noninferiority RCT (September 2023 to April 2025), with follow-up completed in May 2025, recruiting 276 patients with suspected DME referred from a territory-wide diabetic retinopathy screening program. INTERVENTIONS: RCT participants were randomized to intervention (referral for DME evaluation based on both fundus photograph-based screening reports and AI-OCT reports [n = 137]) or control (automatic referral based solely on fundus photograph-based screening reports [n = 139]) groups. The AI-OCT system incorporated image-quality assessment, DME detection, and uncertainty flagging. Study outcomes focused on referral rates under the 2 pathways; for ethical reasons, all participants ultimately underwent specialist evaluation. MAIN OUTCOMES AND MEASURES: The primary outcome was false-positive DME referral rate, with a prespecified noninferiority margin of 20%. The secondary outcomes included sensitivity and specificity for DME detection and DME referral. RESULTS: In prospective silent-mode validation (mean age, 64.7 [SD, 9.4] years; 56.2% male), 86 of 1200 scans (7.2%) were identified as ungradable and 49 of 1114 gradable scans (4.4%) were classified as uncertain. The system achieved 98.8% (95% CI, 94.5%-100.0%) sensitivity and 90.7% (95% CI, 88.7%-92.4%) specificity for DME detection. In the RCT (mean age, 63.9 [SD, 10.9] years; 54.7% male), DME prevalence was similar in the intervention and control groups (30.9% vs 29.9%). The false-positive DME referral rate was 24.1% (95% CI, 14.6%-37.0%) and 69.1% (95% CI, 61.0%-76.1%), respectively (absolute difference, -45% [95% CI, -58.2% to -31.9%; P < .001 for noninferiority]; upper bound of the CI below the prespecified noninferiority margin of 20%). Sensitivity for DME referral was 100.0% (95% CI, 100.0%-100.0%) in both groups. Specificity for DME referral was 86.5% (95% CI, 79.3%-92.9%) in the intervention group and 0.0% (95% CI, 0.0%-0.0%) in the control group. No cases of DME occurred among nonreferred participants in the intervention group. CONCLUSIONS AND RELEVANCE: Compared with standard practice, incorporation of the AI-OCT system as a secondary screening tool was noninferior with respect to false-positive referral rates and was associated with a substantial reduction in potentially unnecessary DME referrals without compromising sensitivity. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2300075087.
引用
- Zhang S, Ran A, Zhou J, et al. An AI-Based OCT System to Detect Diabetic Macular Edema: A Prospective Validation and Noninferiority Randomized Clinical Trial. JAMA. 2026. PMID: 42295755. doi:10.1001/jama.2026.7025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。